| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including cancer cell signaling pathways, inflammatory mediators, and immune cells. Ganoderic acid LM2, as a lanostane-type triterpenoid from Ganoderma lucidum, exhibits anticancer, hepatoprotective, anti-inflammatory, and immunomodulatory activities. The compound may inhibit tumor cell proliferation, induce apoptosis, modulate inflammatory responses, and regulate immune function. Its mechanism of action may involve modulation of signaling pathways such as PI3K/Akt, NF-κB, and MAPK, similar to other ganoderic acids.
|
|---|---|
| ln Vitro |
Ganoderic acid LM2 exhibits anticancer, hepatoprotective, anti-inflammatory, and immunomodulatory activities characteristic of Ganoderma triterpenoids. It may inhibit tumor cell proliferation and induce apoptosis in cancer cell lines. The compound may modulate inflammatory responses and immune function. Its specific in vitro activities depend on the concentrations tested and the assay systems used. Further studies are needed to fully characterize its activity profile.
|
| ln Vivo |
In vivo studies of ganoderic acid LM2 are limited. As a triterpenoid from Ganoderma lucidum, it may contribute to the pharmacological effects of Reishi mushroom, which has been used in traditional medicine for its health-promoting properties. The compound's anticancer, hepatoprotective, anti-inflammatory, and immunomodulatory activities suggest potential benefits in various disease models. Further in vivo studies are needed to characterize its specific pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for ganoderic acid LM2 include enzyme inhibition studies to assess its effects on signaling pathways. Antioxidant activity is assessed using DPPH, ABTS, or FRAP assays. Anti-inflammatory activity is measured by inhibition of COX-2, LOX, or cytokine production in enzyme assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization and purity assessment.
|
| Cell Assay |
Cell-based assays for ganoderic acid LM2 use various cell lines to assess its biological activities. Cancer cell lines are used to assess antiproliferative and pro-apoptotic activities. Macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and treated with the compound, and inflammatory mediators in culture supernatant are measured. For immunomodulatory studies, immune cells are treated with the compound and cytokine production or proliferation is assessed.
|
| Animal Protocol |
In vivo studies of ganoderic acid LM2 are limited. Based on its biological activities, potential animal models include: tumor xenograft models for anticancer evaluation; CCl₄- or APAP-induced liver injury models for hepatoprotective evaluation; carrageenan-induced paw edema models for anti-inflammatory evaluation; and immune modulation models. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Ganoderic acid LM2 has a molecular formula of C₃₀H₄₆O₇ and a molecular weight of approximately 518.68 g/mol. The CAS number is 508182-41-0. It is a lanostane-type triterpenoid isolated from Ganoderma lucidum (Reishi). Ganoderma lucidum has been used in traditional medicine for its health-promoting properties. The compound should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ganoderic acid LM2 are limited. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have low toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
Derived from the fruiting body of Ganoderma lucidum; structure can be found in the first reference.
Ganoderic acid LM2 is a triterpenoid compound isolated from the medicinal mushroom Ganoderma lucidum (Reishi). Ganoderma lucidum has been used in traditional medicine for its health-promoting properties, including immune modulation, anti-inflammatory, and anticancer effects. Ganoderic acids are a class of lanostane-type triterpenoids known for their diverse biological activities. Ganoderic acid LM2 is used as a research tool for studying the pharmacology of Ganoderma triterpenoids and their potential therapeutic applications. It is for research use only. |
| Molecular Formula |
C30H42O7
|
|---|---|
| Molecular Weight |
514.65
|
| Exact Mass |
514.293
|
| CAS # |
508182-41-0
|
| PubChem CID |
11813266
|
| Appearance |
White to light yellow solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
715.0±60.0 °C at 760 mmHg
|
| Flash Point |
400.2±29.4 °C
|
| Vapour Pressure |
0.0±5.2 mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
37
|
| Complexity |
1130
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O[C@H]1CC2C(C)(C)C(CC[C@]2(C)C2C(C[C@]3(C)[C@@]([H])([C@H](C)C[C@@H](/C=C(/C(=O)O)\C)O)CC([C@@]3(C)C=21)=O)=O)=O
|
| InChi Key |
YVIVANDTNNUXRH-LEWHDHFNSA-N
|
| InChi Code |
InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h11,15,17-19,21,31-32H,8-10,12-14H2,1-7H3,(H,36,37)/b16-11+/t15-,17+,18-,19+,21+,28+,29-,30+/m1/s1
|
| Chemical Name |
(E,4S,6R)-4-hydroxy-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
|
| Synonyms |
Ganoderic acid LM2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (97.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL | |
| 5 mM | 0.3886 mL | 1.9431 mL | 3.8861 mL | |
| 10 mM | 0.1943 mL | 0.9715 mL | 1.9431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
